RDB07626 - pRx-IRES-bsr-hVEGF

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pRx-IRES-bsr-hVEGF (#RDB07626)

Gene/insert name	Human cDNA
Depositor\|Developer	Hamada, Hirofumi \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested (Ishii, K. et al., J. Gene Med. 10 (6): 597-609, 2008; Tanaka, T. et al., Clin. Cancer Res. 12 (12): 3803-3813, 2006). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.

Remarks Remember that you will be working with samples containing infectious virus.

提供案内 (日本国内) [open/close]

Terms and conditions for distribution	The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested (Ishii, K. et al., J. Gene Med. 10 (6): 597-609, 2008; Tanaka, T. et al., Clin. Cancer Res. 12 (12): 3803-3813, 2006). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Remarks	Remember that you will be working with samples containing infectious virus.

MTAに書く使用条件	非営利機関の非営利学術研究へ提供する。利用者が本件リソースを利用した研究成果に基づき特許申請、商業活動等を行う場合、利用者は事前に寄託者に連絡する。利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Ishii, K. et al., J. Gene Med. 10 (6): 597-609, 2008; Tanaka, T. et al., Clin. Cancer Res. 12 (12): 3803-3813, 2006)。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。
備考	このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。

MTAに書く使用条件

非営利機関の非営利学術研究へ提供する。利用者が本件リソースを利用した研究成果に基づき特許申請、商業活動等を行う場合、利用者は事前に寄託者に連絡する。利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Ishii, K. et al., J. Gene Med. 10 (6): 597-609, 2008; Tanaka, T. et al., Clin. Cancer Res. 12 (12): 3803-3813, 2006)。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。

備考

このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。

Catalog #	Resource name	Availability	Shipping form	Fee (non-profit org.)
RDB07626	pRx-IRES-bsr-hVEGF	Under QC test. Please contact us.	Please contact us.	JPY 9,460 (not-for-profit academic purpose) plus cost of shipping containers, dry ice (if required) and shipping charge